Fluidic Analytics Fluidity One-W Serum for in-solution affinity profiling

Click2Contact

Fluidity One‑W Serum is a novel in-solution immunoassay platform that allows researchers to characterise and quantify antigen-antibody interactions directly in minimally diluted serum.

Traditional immunoassays such as ELISAs combine affinity and concentration into a single, less-precise measure known as titre, which cannot readily distinguish between large numbers of weak-binding antibodies and small numbers of strong-binding antibodies. Other technologies which rely on attaching antigens to surfaces have the ability to measure affinity in purified systems, but experience difficulty doing so in complex backgrounds such as plasma and serum due to non-specific binding and other surface constraints. These limitations can have major implications for plasma transfer treatments, vaccine and therapeutic development, and the ongoing monitoring of immunity.

The Fluidity One‑W Serum has the ability to independently quantify antibody affinity and concentration directly in patient serum, which should allow a deeper, more accurate understanding of the immune system.

Other product highlights include: characterisation of protein interactions in solution using microfluidic diffusional sizing (MDS); the ability to measure in complex backgrounds such as minimally diluted serum; no binding artefacts or non-specific binding; no surface constraints; independent determination of antibody concentration and affinity for a comprehensive immune response assessment; an easy-to-use interface and consumable management; and disposable single-use chips and contained waste, minimising the risk of cross-contamination.

For more information: https://www.fluidic.com/resources/solution-phase-affinity-profiling-of-a-SARS-CoV-2/.